HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND Russian patent published in 2021 - IPC C07D333/36 C07D409/04 C07D409/12 C07D409/14 C07D417/12 A61K31/381 A61K31/427 A61K31/4436 A61P1/16 

FIELD: medicine; pharmaceutics.

SUBSTANCE: group of inventions relates to the field of medicine and pharmaceutics, more specifically to the use of a compound represented by the general formula (I), in which A is phenyl ring, thiophene ring or isothiazole ring; R¹ are the same or different, and are a halogen atom or C₁-C₃ alkyl group; R² is a hydrogen atom or C₁-C₆ alkyl group; p is an integer from 0 to 5; V is CR³, in which R³ is a hydrogen atom, an amino group, a nitro group, or C₁-C₃ alkoxy group, or V is a nitrogen atom; X is an atom of halogen or its pharmacologically acceptable salt for the treatment or prevention of non-alcoholic steatohepatitis (NASH) caused by a receptor of lysophosphatidic acid (LPA). A method for the treatment or prevention of non-alcoholic steatohepatitis (NASH) caused by the receptor of lysophosphatidic acid is also described, including the injection of the compound represented by the general formula (I).

EFFECT: technical result is providing the use of α-halogen-substituted thiophene with strong antagonistic activity relatively to the receptor to LPA for the treatment or prevention of non-alcoholic steatohepatitis.

14 cl, 3 tbl, 154 ex